Nasdaq Sends Delisting Notice to Actuate Therapeutics Over Market Value Shortfall
ACTU sits 24% above its 52-week low of $1.16.
Summary
Actuate Therapeutics received a Nasdaq delisting notice after its market value fell below the $50 million minimum. The company has until January 11, 2027 to regain compliance, but its precarious cash position and going concern warning make this a critical challenge.
Key Events · Legal and Risk Events · ACTU
-
Nasdaq Delisting Notice Received
On July 15, 2026, the company received notice that its Market Value of Listed Securities (MVLS) fell below the $50 million minimum required for continued listing on the Nasdaq Global Market.
-
180-Day Compliance Window
To regain compliance, the company must maintain an MVLS of at least $50 million for ten consecutive business days by January 11, 2027.
-
Going Concern Overlap
The delisting notice compounds existing liquidity pressures; the last 10-Q warned that cash would only fund operations through July 2026, raising doubts about the ability to sustain a $50 million market value.
-
Potential Fallback to Nasdaq Capital Market
If compliance is not regained, the company may apply to transfer to the Nasdaq Capital Market, though success is not assured and delisting remains a risk.
Analysis · ACTU · Life Sciences
A delisting risk has emerged after Nasdaq notified Actuate Therapeutics that its market value of listed securities slipped below the $50 million minimum. The company now has 180 days, until January 11, 2027, to regain compliance by sustaining a market value above $50 million for ten consecutive business days. Already facing a going concern warning with cash only through July 2026, the path to compliance looks uncertain. Failure could force a move to the Nasdaq Capital Market or outright delisting, which would severely impact liquidity and investor confidence.
At the time of this filing, ACTU was trading at $1.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $34.5M. The 52-week trading range was $1.16 to $9.22. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.